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Cardiac Markers of Pre-Clinical
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Objectives Our aim was to evaluate the impact of metabolic syndrome (MetS) on cardiac phenotype in adolescents.
Background A high prevalence of MetS has been reported in adolescents.
Methods Four hundred forty-six nondiabetic American Indian adolescents (age 14 to 20 years, 238 girls) underwent clini-
cal evaluation, laboratory testing, and Doppler echocardiography. Age- and gender-specific partition values were
used to define obesity and hypertension. Metabolic syndrome was defined according to Adult Treatment Panel III
criteria, modified for adolescents. Left ventricular (LV) hypertrophy and left atrial (LA) dilation were identified
using age- and gender-specific partition values.
Results One hundred eleven participants met criteria for MetS. They had a similar age and gender distribution as non-
MetS participants. Analysis of covariance, controlling for relevant confounders, demonstrated that participants
with MetS had higher LV, LA, and aortic root diameters, higher LV relative wall thickness, and greater LV mass
index. Accordingly, MetS participants showed higher prevalences of LV hypertrophy (43.2% vs. 11.7%) and LA
dilation (63.1% vs. 21.9%, both p  0.001) compared with non-MetS participants. In addition, MetS was associ-
ated with a reduction in midwall shortening, lower transmitral mitral early to atrial peak velocity ratio, and mildly
prolonged mitral early deceleration time (all p  0.05). In multiple regression analysis, independently of demo-
graphics, obesity, blood pressure, and single metabolic components of MetS, clustered MetS was associated
with a 2.6-fold higher likelihood of LV hypertrophy and a 2.3-fold higher likelihood of LA dilation (both p  0.02).
Conclusions In a population sample of adolescents, MetS is associated with higher prevalences of LV hypertrophy and LA
dilation and with reduced LV systolic and diastolic function, independently of individual MetS components.
(J Am Coll Cardiol 2008;52:932–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.013o
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ehe metabolic syndrome (MetS) is characterized by
lusters of metabolic risk factors (1), which might in-
rease cardiovascular (CV) risk beyond what is predicted
y single components (2–5). The MetS is associated with
n increased risk of cardiac mortality in the absence of
iabetes and independently of arterial hypertension
6 – 8). It has been previously reported that MetS is
elated to abnormal left ventricular (LV) geometry and
unction in nondiabetic adults with a high prevalence of
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omponent most strongly associated with markers of
re-clinical CV disease even in the absence of tradition-
lly defined hypertension (9).
See page 939
The rising prevalence of obesity and hypertension among
hildren and adolescents is now a major health concern with
oth epidemiological and economic implications (9–12).
e have already reported that LV hypertrophy can be
ound in 30% of obese adolescents at a mean age 18 years,
espite a low prevalence of hypertension (13). And it has
lso been observed that obese adolescents often have MetS,
uggesting that the increased LV mass might be a response
ot only to increased hemodynamic load but also to possible
eurohormonal effects of clustered metabolic factors influ-
ncing LV growth (13). To date, little information is
vailable on whether the presence of MetS is associated with
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September 9, 2008:932–8 MetS and Heart in Adolescentsignificant cardiac abnormalities in adolescents, or whether
he impact of MetS on cardiac phenotype is independent of
he single components of the syndrome. Accordingly, the
resent analysis has been designed to study the CV effects of
etS in adolescents from a population-based sample.
ethods
tudy population. The SHS (Strong Heart Study) is a
ongitudinal study of CV risk factors and prevalent and
ncident CV disease in American Indian communities in
rizona, Oklahoma, and North/South Dakota. As previ-
usly described (14), 4,549 members of 13 tribes age 45 to
4 years were recruited from defined sampling frames
overall participation rate 61%) for baseline examination
n July 1989 to January 1992. The fourth SHS examination
13), conducted in 2001 to 2003, enrolled members of large
-generation families, ascertained by having multiple family
embers in the initial SHS cohort, which included a total
f 460 adolescent participants (age 20 years, mean 17.3 
.5 years; 53.2% female participants). After excluding par-
icipants with American Diabetes Association–defined di-
betes (n  10) and/or significant valvular disease (n  4),
46 adolescents (14 to 20 years of age) were included in
he present analysis.
hysical examination and laboratory testing. The exam-
nation included medical history, computerized electrocar-
iogram, measurement of brachial blood pressure, fasting
lucose and insulin, glycated hemoglobin, lipid and lipopro-
ein levels, and a 2-h, 75-g glucose tolerance test (15). Blood
ressure was measured as recommended by the Fifth Report
f the Joint National Committee on Prevention, Detection,
valuation, and Treatment of High Blood Pressure (15).
aboratory tests and anthropometric measures (weight,
eight, and waist circumferences) were taken as previously
eported (16). Fat-free mass and adipose body mass were
stimated by the use of an RJL impedance meter (model
14101, RJL Equipment Co., Clinton Township, Mis-
ouri) and equations based on total body water validated in
he American Indian population (17).
efinition of obesity, hypertension, and MetS. As rec-
mmended, 95th percentiles of body mass index (BMI)-
or-age charts developed by the National Center for Health
tatistics (18) were used to define obesity. Guidelines
orrection was applied (19) so that the limit separating
verweight and obesity did not exceed a BMI of 30 kg/m2.
For adolescents 18 years of age and younger, hypertension
as assessed by using age-, gender-, and height-specific
artition values according to the Fourth Report on the
iagnosis, Evaluation, and Treatment of High Blood Pres-
ure in Children and Adolescents (20). For adolescents
lder than 18 years of age, recommendations from the
eventh Report of the Joint National Committee on Pre-
ention, Detection, Evaluation, and Treatment of High
lood Pressure were followed (21). The MetS was prelim-narily identified using the Adult Treatment Panel III (ATP DII) (22) definition (with parti-
ion value of 100 mg/dl for fast-
ng glucose), and then applying
he ATP III modified definition
eveloped by Jolliffe and Janssen
23) for adolescents. Under both
riteria, MetS was diagnosed
hen at least 3 of the 5 com-
onents of the syndrome (in-
reased waist circumference,
igh blood pressure, high tri-
lycerides, high fasting glucose,
nd low high-density lipopro-
ein cholesterol [HDL-C]) ex-
eeded age- and gender-specific
artition values (Online Ap-
endix).
chocardiography. Echocar-
iograms were performed by ex-
ert sonographers, according to standardized methods, and
eviewed off-line by 2 independent readers (M.C., R.B.D.)
sing a computerized review station with digitizing tablet
nd monitor screen overlay for calibration and performance
f needed measurements (24). Left ventricular internal
imension, and septal and posterior wall thickness were
easured at end-diastole and -systole by American Society
f Echocardiography recommendations on 3 cycles (25,26).
s previously described (27), left atrial (LA) anteroposterior
iameter was measured in long-axis views in end-systole,
nd aortic root diameter was measured at the level of the
inus of Valsalva in end-diastole. Since normal LA size in
hildren increases with growth (28), LA diameter was
ormalized for body height to account for differences in
ody maturation. Partition values to detect LA dilation were
.23 cm/m in boys and 2.11 cm/m in girls, representing
ge-, gender-, and ethnic-specific 95th percentiles derived
n a subgroup of 92 normal adolescent participants. A
ecropsy-validated formula was used to calculate LV mass
29), which was normalized for body height in meters to the
llometric power of 2.7, which linearizes the relation be-
ween LV mass and height (i.e., body growth) and identifies
he impact of excess body weight (30). Partition values for
he definition of LV hypertrophy were 40.75 g/m2.7 for boys
nd 38.49 g/m2.7 for girls, representing previously reported
ge-, gender-, and ethnic-specific cutoff points (13). To
valuate the concentricity of LV geometry, myocardial
hickness (wall  septum) was divided by LV minor axis
diameter) to generate relative wall thickness (RWT). Be-
ause normal RWT increases with age (31), its raw value
as adjusted for age (RWTa) by previously reported equa-
ions (31). Left ventricular systolic performance was as-
essed by LV ejection fraction and by LV shortening
easured at the midwall level (midwall shortening) (32).
troke volume was determined by an invasively validated
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
CV  cardiovascular
HDL-C  high-density
lipoprotein cholesterol
LA  left atrium/atrial
LV  left
ventricle/ventricular
MetS  metabolic
syndrome
OR  odds ratio
RWT  relative wall
thickness
RWTa  relative wall
thickness age-adjustedoppler method (33) and used to calculate cardiac output.
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MetS and Heart in Adolescents September 9, 2008:932–8Left ventricular diastolic properties were assessed by
oppler interrogation of transmitral peak early (E) and late
A) velocities and by measurement of the deceleration time
f peak E velocity. Isovolumic relaxation time was measured
etween mitral valve closure and aortic valve opening.
tatistical analysis. Statistical analyses were performed
sing SPSS 12.0.0 (SPSS Inc., Chicago, Illinois) software.
ata are presented as mean  SD for continuous variables
nd as proportions for categorical variables. Descriptive
tatistics were based on normal or chi-square distributions.
he population was dichotomized according to the presence
f MetS. Comparison of demographics and laboratory tests
as performed by independent t test. Comparison of cardiac
eometry and function was performed by analysis of covari-
nce adjusting for differences in age, gender, heart rate, and
ody height (considered an estimate of body maturation at
given age and gender). In addition, binary logistic multiple
egression modeling was performed, controlling for con-
ounders (age and gender), with the specific aim of deter-
ining whether clustered MetS confers additional indepen-
ent risk of presenting markers of pre-clinical CV disease
i.e., LV hypertrophy and LA dilation) over and above the
ffects of single-component risk factors. Covariates were
ntered in the model using a hierarchical enter procedure in
he following order: 1) age and gender; 2) presence of
besity; 3) systolic blood pressure; 4) single metabolic
omponents of MetS (including fasting glucose, HDL-C,
nd triglycerides); and 5) presence of MetS. Alternative
odels were also performed replacing obesity with waist
ircumference, and fasting glucose with either plasma insu-
in or homeostasis model assessment (HOMA) index.
esults
istribution of risk factors. Adult ATP III criteria for the
efinition of MetS identified 71 participants with the
yndrome (15.9% of population, 53.5% girls). According to
he adolescent criteria, MetS was instead present in 111
articipants (24.9% of population, 55.9% girls; kappa score
etween criteria  0.66) with similar prevalence in women
26.3%) and men (23.3%; p  NS). The most prevalent
omponent of the MetS by the adolescent definition was
ncreased waist circumference (54.3%), followed by low
DL-C (46.4%), high blood pressure (30.3%), increased
riglycerides (27.8%), and increased fasting glucose (2.5%).
f the 446 participants, 102 (22.9%) had no component of
he MetS, 116 (26%) had only 1 MetS component, 117
26.2%) had 2 clustered risk factors, 77 (17.3%) had 3, 32
7.2%) had 4, and only 2 participants (0.4%) showed
lustered presence of all 5 risk factors.
linical and laboratory characteristics of the population
y MetS class. Participants with MetS had similar age,
ender distribution, and heart rate compared with non-
etS participants (Table 1). Comparison of anthropomet-
ics, body composition, and laboratory tests identified the
xpected unfavorable phenotype in the MetS participants as Bpposed to non-MetS participants, characterized by higher
at and fat-free body mass, higher BMI, and higher blood
ressure values. Prevalences of obesity and hypertension were
lso significantly higher in MetS participants (both p 0.001).
similar prevalence of smoking habit and alcohol drinking
as observed between the 2 groups (p  NS).
Metabolic characteristics of the study population are
hown in Table 2. As expected, participants with the MetS
howed a worse glycemic profile (higher fasting glucose,
nsulin, and HOMA index), worse lipid profile (higher total
holesterol, low-density lipoprotein cholesterol, and triglyc-
rides, and lower HDL-C), and higher values of plasma
brinogen, with similar plasma creatinine levels between
roups.
ardiac geometric and functional characteristics by
etS class. After adjustment for age, gender, height, and
eart rate, LV chamber size (diameter), aortic root, and LA
iameter were greater in MetS adolescents compared with
on-MetS adolescents (Table 3). Left ventricular mass and
WTa were also significantly higher in MetS participants
all p  0.0001). Accordingly, prevalence of LA dilation
63.1% vs. 21.9%) and LV hypertrophy (43.2% vs. 11.7%)
ere markedly higher in the presence of MetS (both p 
.001). Stroke volume and cardiac output were increased in
etS participants, due to enlarged LV chamber size.
jection fraction was similar in the 2 groups; in contrast,
idwall shortening was lower in MetS than in non-MetS
dolescents. Finally, MetS adolescents exhibited a signifi-
antly lower transmitral E/A ratio and slightly longer
eceleration time of E velocity, but no significant difference
n isovolumic relaxation time. Results were also confirmed
hen applying adult ATP III criteria for the definition of
etS (data not shown).
redictors of LA dilation and LV hypertrophy. In uni-
ariate binary logistic regression, LA dilation was predicted
ainly by the presence of obesity (odds ratio [OR]: 26.26;
5% confidence interval [CI]: 10.33 to 66.77; p  0.001)
nd higher systolic blood pressure (OR: 1.04 per mm Hg;
linical Characteristics of Studyarti ipants Wi h and Without MetS
Table 1 Clinical Characteristics of StudyParticipants With and Without MetS
No MetS
(n  335)
MetS
(n  111) p Value
Age (yrs) 17.3 1.4 17.6 1.5 0.072
Women (%) 51.9 55.9 0.511
Fat-free mass (kg) 50.3 10.6 60.1 14.6 0.0001
Adipose mass (kg) 23.8 14.2 45.8 18.8 0.0001
Body mass index (kg/m2) 25.9 6.4 37.0 8.1 0.0001
Systolic BP (mm Hg) 111.2 10.4 120.5 11.4 0.0001
Diastolic BP (mm Hg) 67.8 9.1 75.2 10.0 0.0001
Heart rate (beats/min) 64.7 10.5 65.6 11.9 0.312
Obesity (%) 37.1 92.8 0.0001
Hypertension (%) 3.6 16.2 0.0001
Cigarette smoking (%) 22.1 20.3 0.312
Alcohol drinking (%) 55.2 46.8 0.133P  blood pressure; MetS  metabolic syndrome.
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September 9, 2008:932–8 MetS and Heart in Adolescents5% CI: 1.02 to 1.06; p  0.001), and then by higher
riglycerides (OR: 1.01 per mg/dl; 95% CI: 1.00 to 1.02;
 0.01) and male gender (OR: 1.65; 95% CI: 1.47 to
.77; p  0.01), and negatively by higher HDL-C (OR:
.96 per mg/dl; 95% CI: 0.94 to 0.98; p  0.01), with no
ignificant impact of fasting glucose or age (p  NS). As
hown in Table 4, in hierarchical multivariate regression,
ale gender (OR: 3.32; 95% CI: 1.80 to 6.13), obesity (OR:
.17; 95% CI: 2.62 to 6.66; both p  0.001), and systolic
lood pressure (OR: 1.03; 95% CI: 1.01 to 1.06; p  0.01)
till predicted LA dilation, with no significant impact of age
nd single metabolic components of the MetS. In contrast,
significant effect was observed for clustered MetS, which
onferred an additional 2.3-fold increased risk of LA
ilation (OR: 2.33; 95% CI: 1.14 to 4.73; p  0.020),
ndependently of demographics and single components of
he syndrome.
Similar results were also observed for LV hypertrophy. In
nivariate binary logistic analysis, LV hypertrophy was
redicted mainly by the presence of obesity (OR: 12.10;
5% CI: 4.29 to 33.99; p 0.001) and higher systolic blood
ressure (OR: 1.03 per mm Hg; 95% CI: 1.01 to 1.06; p 
.001), and then by higher triglycerides (OR: 1.02 per
g/dl; 95% CI: 1.01 to 1.04; p  0.05) and older age (OR:
.19 per year; 95% CI: 1.01 to 1.41; p  0.05), and
egatively by higher HDL-C (OR: 0.96 per mg/dl; 95% CI:
.94 to 0.99; p 0.01), with no significant impact of fasting
lucose or gender (p  NS). As shown in Table 5, in
ierarchical multivariate regression, obesity (OR: 2.38; 95%
I: 1.41 to 4.04) and systolic blood pressure (OR: 1.04; 95%
I: 1.01 to 1.07) still predicted LV hypertrophy (both p 
.01), with no significant impact of age, gender, or single
etabolic components of MetS. In contrast, a significant
ffect was observed for clustered MetS, which conferred an
dditional 2.6-fold increased risk of LV hypertrophy (OR:
.57; 95% CI: 1.21 to 5.44; p  0.014), independently of
emographics and single components of the syndrome.
hen the smaller number of participants with MetS by the
dult ATP III definition was evaluated, no additional
etabolic Characteristicsf Study Participants With and Without MetS
Table 2 Metabolic Characteristicsof Study Participants With and Without MetS
No MetS
(n  335)
MetS
(n  111) p Value
Fasting glucose (mg/dl) 89.2 8.4 94.2 8.0 0.0001
Plasma insulin (IU/ml) 13.2 10.7 28.7 37.2 0.0001
Log HOMA index 0.36 0.30 0.70 0.27 0.0001
Triglycerides (mg/dl) 93.6 43.1 178.0 72.3 0.0001
Total cholesterol (mg/dl) 149.7 26.7 168.6 27.7 0.0001
LDL cholesterol (mg/dl) 79.9 23.1 95.1 25.0 0.0001
HDL cholesterol (mg/dl) 51.3 12.1 40.1 10.1 0.0001
Fibrinogen (mg/dl) 341.6 76.4 393.3 73.0 0.0001
Creatinine (mg/dl) 0.79 0.15 0.77 0.13 0.179
DL  high-density lipoprotein; HOMA  homeostasis model assessment; LDL  low-density
ipoprotein; MetS  metabolic syndrome.ndependent risk was found for MetS for either LA dilation vr LV hypertrophy. Alternative models replacing obesity
ith waist circumference, and fasting glucose with either
OMA index or insulin did not significantly change the
eported results. In particular, no independent impact was
bserved for plasma insulin (OR: 1.007 per IU/ml; 95% CI:
.95 to 1.019; p  0.262) or HOMA index (OR: 1.027;
5% CI: 0.98 to 1.075; p  0.259).
iscussion
he present study provides the first evidence of a strong
mpact of MetS on cardiac phenotype in an unselected
opulation of adolescents applying criteria for the definition
f MetS specifically designed for this age range (23,34–36).
o our knowledge, only 1 recent report has attempted to
dentify a possible independent impact of MetS on CV
henotype in adolescents and has failed to show a significant
ssociation between MetS and intima-media thickness (37).
In a previous report that analyzed data of the NHANES
National Health and Nutrition Examination Survey) study,
highly representative study of the U.S., Goodman et al.
34) described a 4.2% prevalence of the MetS in the general
dolescent U.S. population, with a markedly higher preva-
ence, reaching 19.5%, in overweight/obese adolescents
hen applying adolescent-ATP III criteria. The evidence
hat MetS is associated with unfavorable CV phenotype and
nfavorable clinical outcome even in the absence of overt
ypertension and/or diabetes supports the hypothesis that
etS might represent a distinct medical condition, at least
rom an epidemiological point of view (38). The high
revalence of MetS in adults and adolescents has increased
edical attention on the syndrome (11,12,34–36), also
onsidering the increasing burden of obesity and related
etabolic complications found in epidemiological surveys in
ifferent countries (39).
ardiac Characteristics of Studyticipants Wi h and Without MetS
Table 3 Cardiac Characteristics of StudyParticipants With and Without MetS
No MetS
(n  335)
Mets
(n  111) p Value*
LV diameter (cm) 5.21 0.39 5.38 0.44 0.001
Aortic root (cm) 3.03 0.25 3.14 0.31 0.001
Left atrial diameter (cm) 3.31 0.41 3.79 0.35 0.0001
Left atrial dilation (%) 21.9 63.1 0.0001
LV mass (g) 132.3 31.2 157.7 39.1 0.0001
LV mass index (g/m2.7) 32.0 6.1 38.0 7.2 0.0001
LV hypertrophy (%) 10.8 41.8 0.0001
Age-adjusted relative wall thickness 0.27 0.04 0.29 0.04 0.0001
Stroke volume (ml) 78.1 14.2 84.9 14.6 0.0001
Cardiac output (l/min) 5.02 0.99 5.47 1.01 0.0001
Ejection fraction (%) 59.9 4.4 59.7 4.8 0.612
Midwall shortening (%) 18.9 1.5 18.3 1.7 0.001
Mitral E/A ratio 1.86 0.45 1.71 0.40 0.001
E deceleration time (ms) 206.5 36.2 215.9 36.7 0.022
IVRT (ms) 71.9 8.5 79.9 9.1 0.318
Analysis of covariance with Sidak’s adjusted means for age, gender, heart rate, and height.
E/A ratiomitral early to atrial peak velocity ratio; IVRT isovolumic relaxation time; LV left
entricular; MetS  metabolic syndrome.
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MetS and Heart in Adolescents September 9, 2008:932–8In the present study, adolescents with MetS exhibit
orrisome abnormalities of cardiac geometry and function,
ncluding aortic root and LA dilation, a trend towards
oncentric LV geometry, and a remarkably high prevalence
f LV hypertrophy, present in over 40% of MetS adoles-
ents. Furthermore, we found significant impairment in LV
all mechanics and diastolic function (as shown by reduced
itral E/A ratio and prolonged E-wave deceleration time).
nterestingly, the negative effect of MetS on cardiac phe-
otype was independent of the effect of the single risk
actors defining the syndrome, consistent with the concept
hat in adolescents, clustering of risk factors in MetS may
redict CV disease above and beyond the risk associated
ith its single components.
Other authors have reported independent correlations
mong body size, metabolic abnormalities, and LV mass
rowth, in children and adolescents (40,41), but MetS has
ot yet been considered as a pathologic entity in this setting.
he Bogalusa Heart study reported an association between
nsulin and LV mass growth in obese adolescent girls, also
ndependently of blood pressure (42). In the present study,
ultivariate modeling showed that the MetS is associated
ith LV hypertrophy and LA dilation independent of the
ffects of obesity and blood pressure, while single metabolic
isk factors are associated with manifestations of pre-clinical
V disease only in univariate regression.
It has been recently reported that the prevalence of MetS
aries widely in overweight adolescents depending on the
etS definition used (43) and that the instability in the
iagnosis of MetS in adolescents (caused by both gain and
oss of the diagnosis) might imply a reduced clinical utility
f the syndrome (44). In the present study, we have tested
ge- and gender-specific criteria for the definition of MetS,
roposed with the specific aim of minimizing the instability
f the MetS diagnosis in the adolescent age range (23,44).
f note, compared with the adult definition of MetS, the
roposed adolescent criteria were able to identify a strong,
ndependent, and additional impact of the MetS on cardiac
arkers of pre-clinical disease. In addition, although
ollow-up data for the adolescents included in the present
nalysis are not yet available, the significant alteration of CV
ierarchical Multivariate Regression for LA Dilation
Table 4 Hierarchical Multivariate Regression for LA Dilation
p Value OR 95% CI
Step 1 Age (yrs) 0.058 0.842 0.706–1.006
Gender (male) 0.001 3.322 1.800–6.130
Step 2 Presence of obesity 0.001 4.174 2.617–6.657
Step 3 Systolic blood pressure
(mm Hg)
0.015 1.032 1.006–1.059
Step 4 HDL-C (mg/dl) 0.171 0.985 0.965–1.006
Fasting glucose (mg/dl) 0.644 0.992 0.960–1.025
Triglycerides (mg/dl) 0.557 0.999 0.994–1.003
Step 5 MetS 0.020 2.326 1.143–4.734
I  confidence interval; HDL-C  high-density lipoprotein cholesterol; LA  left atrial; MetS 
etabolic syndrome; OR  odds ratio.henotype identified in the presence of MetS strongly Luggests that the diagnosis of MetS even obtained from a
ingle clinical examination should encourage prompt life-
tyle risk-reducing interventions in otherwise healthy ado-
escents.
tudy limitations. The present study has been performed
n American Indians, an ethnic group in which adolescent-
TP III criteria were not specifically tested in NHANES.
owever, in our sample of adolescents with a high preva-
ence of obesity, the MetS was present in 25% of the
opulation, similar to the prevalences reported in NHANES
n the obese/overweight U.S. adolescent population (34). As
uggested by current guidelines for the definition of MetS,
e have applied waist circumference partition values to
dentify the presence of abdominal obesity, although in-
reasing evidence suggests that a direct measure of intra-
bdominal fat should be preferred. However, it has been
ecently shown in a population-based sample of boys and
irls that waist circumference offers a feasible alternative to
he magnetic resonance imaging estimation of intra-
bdominal adipose tissue (45). Finally, Tanner stage was not
etermined, and the relation between body maturation and
ardiac geometry/function could not be investigated. Of
ote, both LV mass and LA diameter were indexed by
eight, a method that has been previously shown to correct
or body growth (29); in addition, all but 2 participants were
15 years of age, thereby minimizing the proportion of
re-pubertal participants.
onclusions
n a population-based sample of adolescents, MetS was
ssociated with high prevalences of LV hypertrophy and LA
ilation, and with increased aortic root diameter and im-
airment in both systolic and diastolic LV performance.
he impact of the MetS on cardiac markers of pre-clinical
isease was independent and additional to obesity, blood
ressure, and single metabolic abnormalities, suggesting
hat, also in adolescents, the risk associated with MetS
ight be beyond what is predicted by single risk factors.
ur findings, paired with previous studies reporting a steep
ncrease in the prevalence of obesity and associated meta-
olic abnormalities in children and young adults, suggest
ierarchical Multivariateegression for LV Hypertrophy
Table 5 Hierarchical MultivariateRegression for LV Hypertrophy
p Value OR 95% CI
Step 1 Age (yrs) 0.368 1.093 0.900–1.328
Gender (male) 0.518 1.241 0.645–2.386
Step 2 Presence of obesity 0.001 2.385 1.408–4.041
Step 3 Systolic blood pressure
(mm Hg)
0.006 1.041 1.012–1.071
Step 4 HDL-C (mg/dl) 0.407 0.990 0.966–1.014
Fasting glucose (mg/dl) 0.262 0.980 0.945–1.016
Triglycerides (mg/dl) 0.946 1.000 0.995–1.004
Step 5 MetS 0.014 2.565 1.210–5.438V  left ventricular; other abbreviations as in Table 4.
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September 9, 2008:932–8 MetS and Heart in Adolescentshat the presence of MetS in adolescents should prompt
ggressive lifestyle modifications to reduce the increasing
urden of future CV disease.
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APPENDIX
or a complete explanation of the partition values for the definition of
etabolic syndrome, please see the online version of this article.
